Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Download All
Learn more about Ki67 testing and learn how to accurately interprete and apply the test results for the optimal selection of therapy for patients with HR-positive, HER2-negative early breast cancer.
person default
Sunil Badve, MD, FRCPath


Are you testing for Ki67 expression levels in patients with early-stage hormone receptor-positive/HER2-negative breast cancer? Read this commentary for a pathologist’s perspective on Ki67 testing.

person default Sunil Badve, MD, FRCPath Released: December 28, 2021
Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
This activity is supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings